Loading stock data…
MOLN
$4.24+0.01 (+0.24%)
Market ClosedLast close May 1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Molecular Partners AG in the Healthcare sector is trading at $4.24. The stock is currently 21% below its 52-week high of $5.36, remaining 2.9% above its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why MOLN maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.24
Potential Upside
5%
Whystock Fair Value$4.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$166.85M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-76.75%
Volume
Today's trading volume
2,071
Recent News
3 European Penny Stocks With Market Caps Under €600M
The European stock market has recently experienced a positive shift, with the STOXX Europe 600 Index climbing by 3.92% amid hopes for a resolution to Middle East tensions. As investors navigate these fluctuating conditions, penny stocks—often smaller or newer companies—remain an intriguing area of exploration. Despite being an older term, penny stocks can present unique opportunities when they possess strong financials and growth potential, offering investors the chance to uncover hidden...
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready
Molecular Partners (NASDAQ:MOLN) hosted a webcast to discuss clinical imaging and dosimetry data for MP0712, its DLL3-targeting radiotherapeutic program, following a presentation at the Theranostics World Conference in South Africa. Company executives said the data came from a named patient access p
Molecular Partners AG (VTX:MOLN) is definitely on the radar of hedge funds investors who own 50% of the company
Key Insights Given the large stake in the stock by institutions, Molecular Partners' stock price might be vulnerable to...
Stocks Look Set to Open Trading Session Marginally Lower Wednesday as Investors Look Ahead to Nvidia Earnings
US stocks look set to open flat in Wednesday's trading session as investors await Nvidia's Q2 result